Blood B-type natriuretic peptide changes in different periods and different cardiac pacing modes

International Heart Journal

Volumn 46, Issue 6, 2005, Pages 1015-1022

  Wang, Ruxing ^a   Li, Xiaorong ^a   Jang, Wenping ^b   Liu, Zhihua ^b   Yang, Xiangjun ^b   Xiao, Chunhui ^a   Shao, Lizheng ^a   Zhu, Jianqiu ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

B type natriuretic peptide; Congestive heart failure; Nonphysiologic pacing; Pacing mode; Physiologic pacing

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; ATRIOVENTRICULAR CONDUCTION; BRADYCARDIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART ARRHYTHMIA; HEART PACING; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; HEART MUSCLE CONDUCTION SYSTEM; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; BIOLOGICAL MARKERS; BRADYCARDIA; CARDIAC PACING, ARTIFICIAL; FEMALE; HEART CONDUCTION SYSTEM; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PACEMAKER, ARTIFICIAL;

EID: 30444454808     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.46.1015     Document Type: Article

References (23)

1. Sinha AM, Filzmaier K, Breithandt OA, et al. Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy of long-term cardiac resynchronization therapy in patients with heart failure. Am J Cardiol 2003; 91: 755-8.
2. Horie H, Tsutamoto T, Minai K, Hayashi M, Kito O, Kinoshita M. Brain natriuretic peptide predicts chronic atrial fibrillation after ventricular pacing in patients with sick sinus syndrome. Jpn Circ J 2000; 64: 965-70.
3. Molhoek SG, Bax JJ, van Erven L, et al. Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy. Heart 2004; 90: 97-8.
4. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 322: 78-81.
5. Mcnairy M, Gardetto N, Clopton P, et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide. Am Heart J 2002; 143: 406-11.
6. Maisel A. B-type natriuretic peptide levels: diagnostic and therapeutic potential. Cardiovasc Toxicol 2001; 1: 159-64. (Review)
7. Maisel A. B-type natriuretic peptide in the diagnosis and management of congestive heart failure. Cardiol Clin 2001; 19: 557-71. (Review)
8. Villacorata H, Duarte A, Duarte NM, et al. The role of B-type natriuretic peptide in the diagnosis of congestive heart failure in patients presenting to an emergency department with dyspnea. Arq Bras Cardiol 2002; 79: 569-72.
9. Logeart D, Saudubray C, Beyne P, et al. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol 2002; 40: 1794-800.
10. Struthers AD. Prospects for using a blood sample in the diagnosis of heart failure. QJM 1995; 88: 303-6.
11. Mair J, Hammerer-Lercher A, Puschendort B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001; 39: 571-88. (Review)
12. Maisel A. B-type natriuretic peptide in the diagnosis and management of congestive heart failure. Cardiol Clin 2001; 19: 557-71. (Review)
13. van der Sloot JA. New developments in the management of heart failure: a review of the literature in 2002. Neth J Med 2003; 61: 19-27. (Review)
14. Bhatia V, Nayyar P, Dhindsa S. Brain natriuretic peptide in diagnosis and treatment of heart failure. J Postgrad Med 2003; 49: 182-5. (Review)
15. RX Wang, XR Li. Changes and clinical implications of B type natriuretic peptide after cardiac pacing. Chin J Cardiac Pacing Electrophysiol 2004; 18: 392-3.
16. Wu X, Seino Y, Ogura H, Fukuma N, Katoh T, Takano T. Plasma natriuretic peptide levels and daily physical activity in patients with pacemaker implantation. Jpn Heart J 2001; 42: 471-82.
17. Horie H, Tsutamoto T, Ishimoto N, et al. Plasma brain natriuretic peptide as a biochemical marker for atrioventricular sequence in patients with pacemakers. Pacing Clin Electrophysiol 1999; 22: 282-90.
18. Hoijer CJ, Brandt J, Willenheimer R, Juul-Moller S, Bostrom PA. Improved cardiac function and quality of life following upgrade to dual chamber pacing after long-term ventricular stimulation. Eur Heart J 2002; 23: 490-7.
19. Mani H, Shirayama T, Suzaki Y, et al. Clinical significance of preserving spontaneous QRS wave in the therapy of DDD pacing for sick sinus syndrome. Pacing Clin Electrophysiol 2004; 27: 1212-6.
20. Abraham WT, Fisher WG, Smith AL, et al. MIRACLE Study Group. Multicenter Insync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-53.
21. Penicka M, Bartunek J, De Bruyne B, et al. Improvement of left ventricular function after cardiac resynchronization therapy is predicted by tissue Doppler imaging echocardiography. Circulation 2004; 109: 978-83.
22. Boriani G, Biffi M, Martignani C, et al. Cardiac resynchronization by pacing: an electrical treatment of heart failure. Int J Cardiol 2004; 94: 151-61. (Review)
23. Bax JJ, Marwick TH, Molhoek SG, et al. Left ventricular dyssynchrony predicts benefit of cardiac resynchronization therapy in patients with end-stage heart failure before pacemaker implantation. Am J Cardiol 2003; 92: 1238-40.